EU and US could reach trade deal this weekend - Reuters
Todd Berard, the Chief Marketing Officer of BioLife Solutions Inc. (NASDAQ:BLFS), has sold a portion of his holdings in the company. According to a recent SEC filing, Berard sold 1,577 shares of BioLife Solutions’ common stock on March 11, 2025. The shares were sold at a price of $25 each, resulting in a total transaction value of $39,425. The transaction comes as BioLife Solutions, with a market capitalization of $1.17 billion, has shown strong momentum with a 49% return over the past year. InvestingPro analysis indicates the stock is currently trading near its Fair Value.
Following this sale, Berard retains ownership of 104,961 shares in the company. This transaction was conducted under a Rule 10b5-1 trading plan, which Berard adopted to manage tax withholding obligations related to the vesting of restricted stock. InvestingPro subscribers can access additional insights, including 7 more ProTips and a comprehensive analysis of BioLife Solutions’ financial health, which is currently rated as GOOD with strong liquidity metrics.
In other recent news, BioLife Solutions reported impressive financial results for the fourth quarter and full year of 2024. The company announced total revenue of $22.7 million for the fourth quarter, surpassing analyst estimates of $21.3 million, and posted a net loss of $2.0 million, which was smaller than the projected loss of $4.4 million. For the full year, BioLife recorded $82.3 million in revenue, excluding contributions from discontinued operations, with a net loss of $11.4 million. The Cell Processing segment was a significant contributor, with a 31% year-over-year increase in revenue to $20.3 million for the fourth quarter. Both H.C. Wainwright and Benchmark have maintained a "Buy" rating for BioLife, with a price target of $30.00, reflecting confidence in the company’s growth prospects. BioLife has also issued optimistic guidance for 2025, projecting total revenue growth of 16-20% and Cell Processing revenue growth of 18-21%. The company’s biopreservation media is now part of 17 approved cell and gene therapies, with expectations for further approvals in the coming year. These developments highlight BioLife’s focus on its high-margin core business following recent divestitures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.